Literature DB >> 18090160

Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the united states: a population-based study.

Yasser H Shaib1, Jessica A Davila, Louise Henderson, Katherine A McGlynn, Hashem B El-Serag.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a highly fatal disease with limited therapeutic options. The determinants, trends, and outcomes of different therapies for ICC are largely unknown in the United States.
METHODS: Using data from the Surveillance, Epidemiology, and End-Results-(SEER) Medicare database, we compared ICC patients receiving different therapies between 1992 and 1999. Univariate and multivariate analyses were performed and adjusted odds ratios (AORs) were calculated. Hazard ratios were calculated for the survival analysis.
RESULTS: Eight hundred sixty-two cases were included. The mean age at diagnosis was 77.9 years (SD=7.1). Only 6.3% received surgical resection, 65.5% received palliative interventions (16.1% surgical, 44.0% endoscopic), 24.4% received only chemo or radiation therapy whereas 3.8% did not receive any treatment. The median survival was 708 days [95% confidence interval (CI): 458-945] for surgical resection, 227 days (95% CI: 182-294) for surgical palliation, and 123 days (95% CI: 108-148) for endoscopic palliation. Patients receiving surgical resection were younger (AOR=5.6, 95% CI: 2.9-11.1), more likely to be diagnosed later in the study period (AOR=2.2, 95% CI: 1.1-4.2), and had better mortality (hazard ratio=0.3, 95% CI: 0.2-0.4). Patients receiving surgical palliation were younger (AOR=1.6, 95% CI: 1.1-2.3), more likely to be diagnosed in the early time period (AOR=1.5, 95% CI: 1.1-2.2), and had similar mortality to those receiving endoscopic palliation.
CONCLUSIONS: Only a minority of patients with ICC receives potentially curative therapy. Young age is the strongest predictor of receiving potentially curative treatment. Older patients and those diagnosed in recent time periods are more likely to receive endoscopic palliation. Surgical resection was associated with improved survival. There was no difference in survival between surgical and endoscopic palliation.

Entities:  

Mesh:

Year:  2007        PMID: 18090160     DOI: 10.1097/MCG.0b013e31802f3132

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  16 in total

Review 1.  Endoscopic treatment options for cholangiocarcinoma.

Authors:  Linda Ann Hou; Jacques Van Dam
Journal:  Hepat Oncol       Date:  2014-03-20

Review 2.  Ablation of Intrahepatic Cholangiocarcinoma.

Authors:  Jennifer Sweeney; Nainesh Parikh; Ghassan El-Haddad; Bela Kis
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

3.  Genetic factors in the pathogenesis of cholangiocarcinoma.

Authors:  Christopher A Wadsworth; Peter H Dixon; Jason H Wong; Michael H Chapman; Siobhan C McKay; Amar Sharif; Duncan R Spalding; Stephen P Pereira; Howard C Thomas; Simon D Taylor-Robinson; John Whittaker; Catherine Williamson; Shahid A Khan
Journal:  Dig Dis       Date:  2011-06-17       Impact factor: 2.404

4.  18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres.

Authors:  Alexander R Haug; Volker Heinemann; Christiane J Bruns; Ralf Hoffmann; Tobias Jakobs; Peter Bartenstein; Marcus Hacker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-10       Impact factor: 9.236

5.  The risk factors and diagnosis of cholangiocarcinoma.

Authors:  Christopher A Wadsworth; Adrian Lim; Simon D Taylor-Robinson; Shahid A Khan
Journal:  Hepatol Int       Date:  2012-11-10       Impact factor: 6.047

6.  A nationwide population-based study shows increasing incidence of cholangiocarcinoma.

Authors:  Teng-Yu Lee; Jaw-Town Lin; Ken N Kuo; Ming-Shiang Wu; Hsiu J Ho; Tzu-Ting Chen; Chun-Ying Wu
Journal:  Hepatol Int       Date:  2012-05-16       Impact factor: 6.047

7.  Intrahepatic cholangiocarcinoma with micrometastasis in the portal tract of the liver.

Authors:  Kenichirou Onuki; Shun-Ichi Ariizumi; Takehiro Ota; Masakazu Yamamoto; Masayuki Nakano
Journal:  Clin J Gastroenterol       Date:  2009-06-16

8.  Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.

Authors:  Matthias Pinter; Wolfgang Sieghart; Michael Reisegger; Friedrich Wrba; Markus Peck-Radosavljevic
Journal:  Wien Klin Wochenschr       Date:  2011-01-19       Impact factor: 1.704

9.  Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study.

Authors:  Jongha Park; Myung-Hwan Kim; Kyu-Pyo Kim; Do Hyun Park; Sung-Hoon Moon; Tae Jun Song; Junbum Eum; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

10.  Kaempferol inhibits the growth and metastasis of cholangiocarcinoma in vitro and in vivo.

Authors:  Youyou Qin; Wu Cui; Xuewei Yang; Baifeng Tong
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-02-15       Impact factor: 3.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.